Abbott Low Dose Kaletra Tablet Clears FDA For Pediatric HIV Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Lower strength tablet formulation will be available at half the cost of full strength tablet in developing countries, according to Abbott.
You may also be interested in...
Abbott Cuts Kaletra Price In 40 Countries
Move follows spat between firm and Thailand over country’s decision to allow generic HIV therapies.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.